Systemic anti-cancer therapy: management options for people with squamous non-small-cell carcinoma

- **PD-L1 <50%**
  - Gemcitabine + Carboplatin* or Cisplatin
  - Vinorelbine + Carboplatin or Cisplatin
- **PD-L1 ≥50%**
  - Pembrolizumab (TA531)
  - Docetaxel
  - Atezolizumab (no PD-L1 expression needed) (TA520)
  - Nivolumab (no PD-L1 expression needed) (TA483)
  - Pembrolizumab (if PD-L1 >1%) (TA428)

Disease progression

Cancer Drugs Fund

*The gemcitabine and carboplatin combination does not have a UK marketing authorisation for this indication

This is a summary of the recommendations on management options for people with squamous cell carcinoma from the NICE guideline on lung cancer ([www.nice.org.uk/guidance/NG122](https://www.nice.org.uk/guidance/NG122)). See the NICE Pathway for an integrated view of all NICE recommendations on lung cancer, and see technology appraisals for full details.

© NICE 2019. All rights reserved. Subject to Notice of rights.